Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomes

Sivaprasad, Sobha, Ghanchi, Faruque, Kelly, Simon P., Kotagiri, Ajay, Talks, James, Scanlon, Peter H ORCID: 0000-0001-8513-710X, McGoey, Hellen, Nolan, Andrew, Saddiq, Moneeb, Napier, Jackie and Morgan-Warren, Peter (2023) Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomes. Eye, 37 (12). pp. 2527-2534. doi:10.1038/s41433-022-02367-x

Preview

Text 12305 Scanlon et al (2023) Evaluation of standard-of-care intravitreal afliberce.pdf - Published Version Available under License Creative Commons Attribution 4.0. Download (949kB) | Preview

Abstract

Background/objectives: DRAKO (NCT02850263) was a 24-month, prospective, non-interventional, multi-centre cohort study enrolling patients with diabetic macular oedema (DMO) including central involvement. The study evaluated UK standard-of-care intravitreal aflibercept (IVT-AFL) treatment. This analysis describes the treatment pathway and service provision for the anti-vascular endothelial growth factor (VEGF) treatment-naïve (C1) and non-naïve patients (C2) who received prior anti-VEGF treatment for DMO other than IVT-AFL. Methods: Mean changes in best-corrected visual acuity and central subfield thickness were measured and stratified by baseline factors, including ethnicity and administration of five initial monthly injections within predefined windows. Clinic visits were classified as treatment only (T1), monitoring assessment only (T2), combined visits (T3) or post-injection visits with no treatment or assessment (T4). Results: Median time from decision to treat to treatment was 6 days. As a percentage of total visits, T1, T2, T3 and T4 were 7%, 42%, 48% and 3% for C1 and 11%, 39%, 48% and 2% for C2. Most IVT-AFL injections were administered by healthcare professionals (HCPs) other than doctors (C1, 57.4%; C2, 58.5%). The percentage of treatments associated with a procedure-related adverse event where at least 75% of injections were completed by the same injector role were similar for doctors and other HCPs (C1, 1.1% and 0.8%; C2, 0.7%, and 1.0%). Conclusions: Results indicate that upon DMO diagnosis, patients were treated promptly, and most visits were combined (treatment and assessment) or monitoring only. Most IVT-AFL was administered by non-physicians with a similar treatment-related safety profile as IVT-AFL administered by physicians.

Item Type:	Article
Article Type:	Article
Uncontrolled Keywords:	Diabetic macular oedema; Intravitreal aflibercept treatment
Subjects:	R Medicine > RE Ophthalmology
Depositing User:	Susan Turner
Date Deposited:	26 Jan 2023 14:11
Last Modified:	15 Aug 2023 13:30
URI:	https://eprints.glos.ac.uk/id/eprint/12305

University Staff: Request a correction | Repository Editors: Update this record